Pseudomonas aeruginosa Phenotypes Associated With Eradication Failure in Children With Cystic Fibrosis

被引:62
|
作者
Mayer-Hamblett, Nicole [1 ,2 ,6 ]
Ramsey, Bonnie W. [1 ,6 ]
Kulasekara, Hemantha D. [3 ]
Wolter, Daniel J. [1 ]
Houston, Laura S. [1 ]
Pope, Christopher E. [1 ]
Kulasekara, Bridget R. [3 ]
Armbruster, Catherine R. [3 ]
Burns, Jane L. [1 ,6 ]
Retsch-Bogart, George [7 ]
Rosenfeld, Margaret [1 ,6 ]
Gibson, Ronald L. [1 ,6 ]
Miller, Samuel I. [3 ,4 ,5 ]
Khan, Umer [6 ]
Hoffman, Lucas R. [1 ,3 ,6 ]
机构
[1] Univ Washington, Dept Pediat, Seattle, WA 98105 USA
[2] Univ Washington, Dept Biostat, Seattle, WA 98105 USA
[3] Univ Washington, Dept Microbiol, Seattle, WA 98105 USA
[4] Univ Washington, Dept Genome Sci, Seattle, WA 98105 USA
[5] Univ Washington, Dept Med, Seattle, WA 98105 USA
[6] Seattle Childrens Hosp, Washington, DC USA
[7] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA
基金
美国国家卫生研究院;
关键词
cystic fibrosis; Pseudomonas aeruginosa; phenotypic characterization; eradication; antibiotic treatment; YOUNG-CHILDREN; COLONY MORPHOLOGY; LUNG-FUNCTION; LASR MUTANTS; INFECTION; ADAPTATION; TOBRAMYCIN; DISEASE; AIRWAYS; DIVERSIFICATION;
D O I
10.1093/cid/ciu385
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Pseudomonas aeruginosa is a key respiratory pathogen in people with cystic fibrosis (CF). Due to its association with lung disease progression, initial detection of P. aeruginosa in CF respiratory cultures usually results in antibiotic treatment with the goal of eradication. Pseudomonas aeruginosa exhibits many different phenotypes in vitro that could serve as useful prognostic markers, but the relative relationships between these phenotypes and failure to eradicate P. aeruginosa have not been well characterized. Methods. We measured 22 easily assayed in vitro phenotypes among the baseline P. aeruginosa isolates collected from 194 participants in the 18-month EPIC clinical trial, which assessed outcomes after antibiotic eradication therapy for newly identified P. aeruginosa. We then evaluated the associations between these baseline isolate phenotypes and subsequent outcomes during the trial, including failure to eradicate after antipseudomonal therapy, emergence of mucoidy, and occurrence of an exacerbation. Results. Baseline P. aeruginosa isolates frequently exhibited phenotypes thought to represent chronic adaptation, including mucoidy. Wrinkly colony surface and irregular colony edges were both associated with increased risk of eradication failure (hazard ratios [95% confidence intervals], 1.99 [1.03-3.83] and 2.14 [1.32-3.47], respectively). Phenotypes reflecting defective quorum sensing were significantly associated with subsequent mucoidy, but no phenotype was significantly associated with subsequent exacerbations during the trial. Conclusions. Pseudomonas aeruginosa phenotypes commonly considered to reflect chronic adaptation were observed frequently among isolates at early detection. We found that 2 easily assayed colony phenotypes were associated with failure to eradicate after antipseudomonal therapy, both of which have been previously associated with altered biofilm formation and defective quorum sensing.
引用
收藏
页码:624 / 631
页数:8
相关论文
共 50 条
  • [41] Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis
    Sunman, Birce
    Emiralioglu, Nagehan
    Hazirolan, Gulsen
    Sener, Burcin
    Ozsezen, Beste
    Tural, Dilber A.
    Buyuksahin, Halime N.
    Guzelkas, Ismail
    Yalcin, Ebru
    Dogru, Deniz
    Ozcelik, Ugur
    Kiper, Nural
    PEDIATRIC PULMONOLOGY, 2022, 57 (06) : 1456 - 1465
  • [42] EARLY DETECTION USING PCR OF PSEUDOMONAS AERUGINOSA INFECTION IN CHILDREN WITH CYSTIC FIBROSIS UNDERGOING ERADICATION TREATMENT
    Blanchard, A. C.
    Coburn, B.
    Zhang, Y.
    Stapleton, P. J.
    Yau, Y.
    Waters, V. J.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S378 - S378
  • [43] THE EFFECTIVENESS OF ROUTINE EARLY ERADICATION OF PSEUDOMONAS AERUGINOSA FOR DELAYING THE DEVELOPMENT OF CHRONIC INFECTION IN CHILDREN WITH CYSTIC FIBROSIS
    Alkadri, J.
    Mostofian, F.
    Tang, K.
    Thampi, N.
    Radhakrishnan, D.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S343 - S343
  • [44] Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment
    Blanchard, Ana C.
    Rooney, Ashley M.
    Yau, Yvonne
    Zhang, Yu
    Stapleton, Patrick J.
    Horton, Eric
    Klingel, Michelle
    Stanojevic, Sanja
    Ratjen, Felix
    Coburn, Bryan
    Waters, Valerie
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (06) : 723 - 728
  • [45] IMPACT OF SUCCESSFUL ERADICATION OF PSEUDOMONAS AERUGINOSA ON LONG TERM OUTCOMES IN CYSTIC FIBROSIS
    Hamblett, N. M.
    Rosenfeld, M.
    Kloster, M.
    Gibson, R.
    Retsch-Bogart, G. Z.
    Thompson, V.
    Ramsey, B.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 317 - 317
  • [46] EVALUATION OF INHALED TOBRAMYCIN IN EARLY ERADICATION OF PSEUDOMONAS AERUGINOSA IN INFANTS WITH CYSTIC FIBROSIS
    Choi, J.
    Novak, K. J.
    Thompson, R.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 275 - 275
  • [47] Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis
    Jackson, Lindsay
    Waters, Valerie
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (01) : 8 - 16
  • [48] No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
    F. Claude
    I. Rochat
    G. M. Hafen
    BMC Research Notes, 12
  • [49] No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
    Claude, F.
    Rochat, I.
    Hafen, G. M.
    BMC RESEARCH NOTES, 2019, 12 (1)
  • [50] Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
    Akkerman-Nijland, Anne M.
    Yousofi, Mina
    Rottier, Bart L.
    Van der Vaart, Hester
    Burgerhof, Johannes G. M.
    Frijlink, Henderik W.
    Touw, Daan J.
    Koppelman, Gerard H.
    Akkerman, Onno W.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14